Celampa M 12.5/1000mg Tablet

Celampa M 12.5/1000mg Tablet is a combination medication that contains two active ingredients: Empagliflozin & Metformin. It is prescribed for the management of type 2 diabetes mellitus to help control blood sugar levels effectively.

Key Ingredients:

1. Empagliflozin: This medication belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. By reducing blood sugar levels, empagliflozin helps manage diabetes.
2. Metformin: Metformin is a biguanide antidiabetic drug that lowers blood sugar levels by decreasing glucose production in the liver and improving insulin sensitivity in the body’s tissues. It also helps to enhance glucose uptake by cells and reduce the absorption of glucose from the intestines.

Uses:

1. Type 2 Diabetes Management: Celampa M 12.5/1000mg Tablet is used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels by combining the effects of empagliflozin and metformin, which work together to improve insulin sensitivity, reduce glucose production, and promote the excretion of glucose in the urine.

Administration:

1. Celampa M 12.5/1000mg Tablet is taken orally, usually once daily with meals or as directed by a healthcare professional.
2. The dosage may vary depending on individual needs, medical history, and response to treatment. It is essential to follow the prescribed dosage and administration instructions provided by the healthcare provider.
3. Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet unless advised otherwise.

Precautions:

1. Before using Celampa M 12.5/1000mg Tablet, inform your healthcare provider about any allergies, medical conditions, or medications you are currently taking, especially other antidiabetic drugs or medications that may interact with empagliflozin or metformin.
2. Regular monitoring of blood sugar levels, kidney function, and electrolyte levels is recommended during treatment with Celampa M 12.5/1000mg Tablet to ensure optimal therapeutic response and detect any potential adverse effects.
3. Patients should be educated about the signs and symptoms of hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) and instructed on how to manage these conditions appropriately.

In Conclusion:

Celampa M 12.5/1000mg Tablet combines empagliflozin and metformin to provide effective management of type 2 diabetes mellitus. By addressing multiple aspects of glucose metabolism, this combination therapy helps improve glycemic control and reduce the risk of diabetes-related complications.